|
1
|
Ravenda V, Manette C, Lemmens R, Mariani
AM, Struvay N and Reginster JY: Prevalence and impact of
osteoarthritis and osteoporosis on health-related quality of life
among active subjects. Aging Clin Exp Res. 19:55–60. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jinks C, Jordan K and Croft P:
Osteoarthritis as a public health problem: The impact of developing
knee pain on physical function in adults living in the community:
(KNEST 3). Rheumatology (Oxford). 46:877–881. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yoshimura N, Muraki S, Oka H, Mabuchi A,
En-Yo Y, Yoshida M, Saika A, Yoshida H, Suzuki T, Yamamoto S, et
al: Prevalence of knee osteoarthritis, lumbar spondylosis and
osteoporosis in Japanese men and women: The research on
osteoarthritis/osteoporosis against disability study. J Bone Miner
Metab. 27:620–628. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qi C and Changlin H: Effects of moving
training on histology and biomarkers levels of articular cartilage.
J Surg Res. 135:352–363. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Garnero P, Rousseau JC and Delmas PD:
Molecular basis and clinical use of biochemical markers of bone,
cartilage and synovium in joint diseases. Arthritis Rheum.
43:953–968. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Garnero P, Piperno M, Gineyts E, Christgau
S, Delmas PD and Vignon E: Cross sectional evaluation of
biochemical markers of bone, cartilage and synovial tissue
metabolism in patients with knee osteoarthritis: Relations with
disease activity and joint damage. Ann Rheum Dis. 60:619–626. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Poole AR: Biochemical/immunochemical
biomarkers of osteoarthritis: Utility for prediction of incident or
progressive osteoarthritis. Rheum Dis Clin North Am. 29:803–818.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rousseau JC and Delmas PD: Biological
markers in osteoarthritis. Nat Clin Pract Rheumatol. 3:346–356.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garnero P and Delmas PD: Biomarkers in
osteoarthritis. Curr Opin Rheumatol. 15:641–646. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Christgau S, Garnero P, Fledelius C, Moniz
C, Ensig M, Gineyts E, Rosenquist C and Qvist P: Collagen type II
C-telopeptide fragments as an index of cartilage degradation. Bone.
29:209–215. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Poole AR, Ionescu M, Fitzcharles MA and
Billinghurst RC: The assessment of cartilage degradation in vivo:
Development of an immunoassay for the measurement in body fluids of
type II collagen cleaved by collagenases. J Immunol Methods.
294:145–153. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shinmei M, Ito K, Matsuyama S, Yoshihara Y
and Matsuzawa K: Joint fluid carboxy-terminal type II procollagen
peptide as a marker of cartilage collagen biosynthesis.
Osteoarthritis Cartilage. 1:121–128. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schwenk TL and Costley CD: When food
becomes a drug: Nonanabolic nutritional supplement use in athletes.
Am J Sports Med. 30:907–916. 2002.PubMed/NCBI
|
|
14
|
Gorsline RT and Kaeding CC: The use of
NSAIDs and nutritional supplements in athletes with osteoarthritis:
Prevalence, benefits and consequences. Clin Sports Med. 24:71–82.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ostojic SM, Arsic M, Prodanovic S, Vukovic
J and Zlatanovic M: Glucosamine administration in athletes: Effects
on recovery of acute knee injury. Res Sports Med. 15:113–124. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fenton JI, Chlebek-Brown KA, Peters TL,
Caron JP and Orth MW: Glucosamine HCl reduces equine articular
cartilage degradation in explant culture. Osteoarthritis Cartilage.
8:258–265. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gouze JN, Bordji K, Gulberti S, Terlain B,
Netter P, Magdalou J, Fournel-Gigleux S and Ouzzine M:
Interleukin-1beta downregulates the expression of
glucuronosyltransferase I, a key enzyme priming glycosaminoglycan
biosynthesis: Influence of glucosamine on
interleukin-1beta-mediated effects in rat chondrocytes. Arthritis
Rheum. 44:351–360. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakamura H, Shibakawa A, Tanaka M, Kato T
and Nishioka K: Effects of glucosamine hydrochloride on the
production of prostaglandin E2, nitric oxide and metalloproteases
by chondrocytes and synoviocytes in osteoarthritis. Clin Exp
Rheumatol. 22:293–299. 2004.PubMed/NCBI
|
|
19
|
Derfoul A, Miyoshi AD, Freeman DE and Tuan
RS: Glucosamine promotes chondrogenic phenotype in both
chondrocytes and mesenchymal stem cells and inhibits MMP-13
expression and matrix degradation. Osteoarthritis Cartilage.
15:646–655. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McAlindon TE, Lavalley MP, Gulin JP and
Felson DT: Glucosamine and chondroitin for treatment of
osteoarthritis: A systematic quality assessment and meta-analysis.
JAMA. 283:1469–1475. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reginster JY, Deroisy R, Rovati LC, Lee
RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE and
Gossett C: Long-term effects of glucosamine sulphate on
osteoarthritis progression: A randomized, placebo-controlled
clinical trial. Lancet. 357:251–256. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pavelká K, Gatterová J, Olejarová M,
Machacek S, Giacovelli G and Rovati LC: Glucosamine sulfate use and
delay of progression of knee osteoarthritis: A 3-year, randomized,
placebo-controlled, double-blind study. Arch Intern Med.
162:2113–2123. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Momomura R, Naito K, Igarashi M, Watari T,
Terakado A, Oike S, Sakamoto K, Nagaoka I and Kaneko K: Evaluation
of the effect of glucosamine administration on biomarkers of
cartilage and bone metabolism in bicycle racer. Mol Med Report.
7:742–746. 2013.
|
|
24
|
Shikhman AR, Brinson DC, Valbracht J and
Lotz MK: Differential metabolic effects of glucosamine and
N-acetylglucosamine in human articular chondrocytes. Osteoarthritis
Cartilage. 17:1022–1028. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shikhman AR, Kuhn K, Alaaeddine N and Lotz
M: N-acetylglucosamine prevents IL-1beta-mediated activation of
human chondrocytes. J Immunol. 166:5155–5160. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shikhman AR, Amiel D, D'Lima D, Hwang SB,
Hu C, Xu A, Hashimoto S, Kobayashi K, Sasho T and Lotz MK:
Chondroprotective activity of N-acetylglucosamine in rabbits with
experimental osteoarthritis. Ann Rheum Dis. 64:89–94. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ozkan FU, Ozkan K, Ramadan S and Guven Z:
Chondroprotective effect of N-acetylglucosamine and hyaluronate in
early stages of osteoarthritis: An experimental study in rabbits.
Bull NYU Hosp Jt Dis. 67:352–357. 2009.PubMed/NCBI
|
|
28
|
Katsuno S, Sato K, Eguchi C, Yoshimura K,
Yamamoto T, Tomonaga A and Nagaoka I: Effects and safety of bilk
beverage containing N-acetyl glucosamine on knee joint pain and
biomarkers of type II collagen metabolism. Jpn Pharmacol Ther.
38:435–445. 2010.
|
|
29
|
Kellgren JH and Lawrence JS: Radiological
assessment of osteo-arthritis. Ann Rheum Dis. 16:494–502. 1957.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cahue S, Sharma L, Dunlop D, Ionescu M,
Song J, Lobanok T, King L and Poole AR: The ratio of type II
collagen breakdown to synthesis and its relationship with the
progression of knee osteoarthritis. Osteoarthr Cartilage.
15:819–823. 2007. View Article : Google Scholar
|
|
31
|
Sharif M, Kirwan J, Charni N, Sandell LJ,
Whittles C and Garnero P: A 5-yr longitudinal study of type IIA
collagen synthesis and total type II collagen degradation in
patients with knee osteoarthritis-association with disease
progression. Rheumatology (Oxford). 46:938–943. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Christgau S, Henrotin Y, Tankó LB, Rovati
LC, Collette J, Bruyere O, Deroisy R and Reginster JY:
Osteoarthritic patients with high cartilage turnover show increased
responsiveness to the cartilage protecting effects of glucosamine
sulfate. Clin Exp Rheumatol. 22:36–42. 2004.PubMed/NCBI
|
|
33
|
Cibere J, Thorne A, Kopec JA, Singer J,
Canvin J, Robinson DB, Pope J, Hong P, Grant E, Lobanok T, et al:
Glucosamine sulfate and cartilage type II collagen degradation in
patients with knee osteoarthritis: Randomized discontinuation trial
results employing biomarkers. J Rheumatol. 32:896–902.
2005.PubMed/NCBI
|
|
34
|
Mazières B, Hucher M, Zaïm M and Garnero
P: Effect of chondroitin sulfate in symptomatic knee
osteoarthritis: A multicentre, randomised, double-blind,
placebo-controlled study. Ann Rheum Dis. 66:639–645. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Julovi SM, Ito H, Nishitani K, Jackson CJ
and Nakamura T: Hyaluronan inhibits matrix metalloproteinase-13 in
human arthritic chondrocytes via CD44 and P38. J Orthop Res.
29:258–264. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yatabe T, Mochizuki S, Takizawa M,
Chijiiwa M, Okada A, Kimura T, Fujita Y, Matsumoto H, Toyama Y and
Okada Y: Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1)
in human osteoarthritic chondrocytes. Ann Rheum Dis. 68:1051–1058.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mladenovic Z, Saurel AS, Berenbaum F and
Jacques C: Potential role of hyaluronic acid on bone in
osteoarthritis: Matrix metalloproteinases, aggrecanases and RANKL
expression are partially prevented by hyaluronic acid in
interleukin 1-stimulated osteoblasts. J Rheumatol. 41:945–954.
2014. View Article : Google Scholar : PubMed/NCBI
|
